

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1 (currently amended): An isolated nucleic acid molecule which comprises ~~DNA~~a polynucleotide having at least about 80% sequence identity to (a) a DNA molecule encoding an FGF-19 polypeptide comprising ~~the sequence of~~ amino acid residues from about 1 or about 23 to about 216 of Figure 2 (SEQ ID NO:2), or (b) the complement of the DNA molecule of (a), wherein the FGF-19 polypeptide reduces total body mass in an individual, reduces fat in an individual, reduces level of triglycerides and free fatty acids in an individual, increases metabolic rate of an individual, induces leptin release from an adipocyte cell, or decreases glucose uptake in an adipocyte cell.

2 (currently amended): The isolated nucleic acid molecule of Claim 1 comprising ~~the sequence of nucleotides~~ positions from about 464 or about 530 to about 1111 of Figure 1 (SEQ ID NO:1).

3 (currently amended): The isolated nucleic acid molecule of Claim 1 comprising the polynucleotide sequence of Figure 1 (SEQ ID NO:1).

4 (currently amended): The isolated nucleic acid molecule of Claim 1 comprising a polynucleotide sequence that encodes ~~the sequence of~~ amino acid residues from about 1 or about 23 to about 216 of Figure 2 (SEQ ID NO:2).

5 (currently amended): An isolated nucleic acid molecule comprising ~~DNA~~a polynucleotide ~~having which comprises~~ at least about 80% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA deposited with the ATCC on November 21, 1997 under ATCC Deposit No. 209480 (DNA49435-1219), or (b) the complement of the DNA molecule of (a), wherein the mature polypeptide reduces total body mass in an individual, reduces fat in an individual, reduces level of triglycerides and free fatty acids in an individual, increases metabolic rate of an individual, induces leptin release from an adipocyte cell, or decreases glucose uptake in an adipocyte cell.

6 (currently amended): The isolated nucleic acid molecule of Claim 5 comprising a polynucleotide~~DNA~~ encoding the same mature polypeptide encoded by the human protein cDNA

deposited with the ATCC on November 21, 1997 under ATCC Deposit No. 209480 (DNA49435-1219).

7 (currently amended): An isolated nucleic acid molecule comprising a polynucleotide DNA which comprises having at least about 80% sequence identity to (a) the full-length polypeptide coding sequence of the human protein cDNA deposited with the ATCC on November 21, 1997 under ATCC Deposit No. 209480 (DNA49435-1219), or (b) the complement of the coding sequence of (a), wherein the polypeptide encoded by the human protein cDNA reduces total body mass in an individual, reduces fat in an individual, reduces level of triglycerides and free fatty acids in an individual, increases metabolic rate of an individual, induces leptin release from an adipocyte cell, or decreases glucose uptake in an adipocyte cell.

8 (original): The isolated nucleic acid molecule of Claim 7 comprising the full-length polypeptide coding sequence of the human protein cDNA deposited with the ATCC on November 21, 1997 under ATCC Deposit No. 209480 (DNA49435-1219).

9 (currently amended): An isolated nucleic acid molecule encoding an FGF-19 polypeptide comprising DNAa polynucleotide that hybridizes under stringent conditions to the complement of the nucleic acid sequencea polynucleotide that encodes amino acid[[s]] residues from about 1 or about 23 to about 216 of Figure 2 (SEQ ID NO:2, wherein stringent hybridization conditions comprise 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C.

10 (currently amended): The isolated nucleic acid molecule of Claim 9, wherein the polynucleotide~~nucleic acid~~ that encodes amino acids from about 1 or about 23 to about 216 of Figure 2 (SEQ ID NO:2) comprises nucleotides from about 464 or about 530 to about 1111 of Figure 1 (SEQ ID NO:1).

11-13 (canceled)

14 (currently amended): A vector comprising the nucleic acid molecule of Claim [[13]] 1
or 4.

15 (original): The vector of Claim 14, wherein said nucleic acid molecule is operably linked to control sequences recognized by a host cell transformed with the vector.

16 (original): A nucleic acid molecule deposited with the ATCC under accession number 209480 (DNA49435-1219).

17 (original): A host cell comprising the vector of Claim 14.

18 (original): The host cell of Claim 17, wherein said cell is a CHO cell.

19 (original): The host cell of Claim 17, wherein said cell is an *E. coli*.

20 (original): The host cell of Claim 17, wherein said cell is a yeast cell.

21 (original): A process for producing an FGF-19 polypeptide comprising culturing the host cell of Claim 17 under conditions suitable for expression of said FGF-19 polypeptide and recovering said FGF-19 polypeptide from the cell culture.

22 (new): The isolated nucleic acid of Claim 1, wherein the polynucleotide has at least about 85% sequence identity to (a) a DNA molecule encoding an FGF-19 polypeptide comprising amino acid residues from about 1 or about 23 to about 216 of Figure 2 (SEQ ID NO:2), or (b) the complement of the DNA molecule of (a).

23 (new): The isolated nucleic acid of Claim 1, wherein the polynucleotide has at least about 90% sequence identity to (a) a DNA molecule encoding an FGF-19 polypeptide comprising amino acid residues from about 1 or about 23 to about 216 of Figure 2 (SEQ ID NO:2), or (b) the complement of the DNA molecule of (a).

24 (new): The isolated nucleic acid of Claim 1, wherein the polynucleotide has at least about 95% sequence identity to (a) a DNA molecule encoding an FGF-19 polypeptide comprising

amino acid residues from about 1 or about 23 to about 216 of Figure 2 (SEQ ID NO:2), or (b) the complement of the DNA molecule of (a).

25 (new): The isolated nucleic acid of Claim 1, wherein the polynucleotide has at least about 99% sequence identity to (a) a DNA molecule encoding an FGF-19 polypeptide comprising amino acid residues from about 1 or about 23 to about 216 of Figure 2 (SEQ ID NO:2), or (b) the complement of the DNA molecule of (a).

26 (new): The isolated nucleic acid molecule of Claim 1 consisting of a polynucleotide sequence that encodes amino acid residues from about 1 or about 23 to about 216 of Figure 2 (SEQ ID NO:2).

27 (new): The isolated nucleic acid molecule of Claim 1 comprising a polynucleotide sequence that encodes amino acid residues from about any of 17 to 27 to about 216 of Figure 2 (SEQ ID NO:2).

28 (new): The isolated nucleic acid molecule of Claim 1, wherein the FGF-19 polypeptide reduces total body mass in an individual.

29 (new): The isolated nucleic acid molecule of Claim 1, wherein the FGF-19 polypeptide reduces fat in an individual.

30 (new): The isolated nucleic acid molecule of Claim 1, wherein the FGF-19 polypeptide reduces level of triglycerides and free fatty acids in an individual.

31 (new): The isolated nucleic acid molecule of Claim 1, wherein the FGF-19 polypeptide increases metabolic rate of an individual.

32 (new): The isolated nucleic acid molecule of Claim 1, wherein the FGF-19 polypeptide induces leptin release from an adipocyte cell.

33 (new): The isolated nucleic acid molecule of Claim 1, wherein the FGF-19 polypeptide decreases glucose uptake in an adipocyte cell.

34 (new): A process for producing an FGF-19 polypeptide comprising culturing a host cell comprising a nucleic acid molecule deposited with the ATCC under accession number 209480 (DNA49435-1219) under conditions suitable for expression of said FGF-19 polypeptide and recovering said FGF-19 polypeptide from the cell culture.

35 (new): A composition comprising the polynucleotide of any of Claims 1, 4, 5, 7, or 9.

36 (new): The host cell of Claim 17, wherein said cell is a mammalian cell.